Elevating Our Communities With Every Interaction

Velocity is the world's leading integrated site organization.

Sponsors and CROs trust Velocity to deliver high-quality clinical trial data and patient care with unprecedented efficiency.

Simplify everything from site selection to study close-out

Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.

+
Research sites across the U.S. and Europe
+
Investigators with diverse experience
+
Clinical trials conducted since 1986
U.S. Department of Health and Human Services (HHS) Officials Meet With Leaders to Discuss COVID-19 Vaccine Clinical Trials and Patient Recruitment
mother-and-child-2
Hallandale
caring african medical nurse comforting senior patient in office
Velocity-team-office

The right sites.
The right investigators.
The right partner for you.

Strategically located to give you access to diverse specialty populations, Velocity's sites are supported by next-gen technologies and patient engagement capabilities. Welcome to recruitment and retention reimagined.

Scale for a purpose: Supporting research programs worldwide

From the leading pharma companies, to the most pioneering biotech startups, Velocity supports those who are exploring new frontiers in human health.

Whether you’re ready to conduct a single-site study or a complex, high-volume clinical trial, contact Velocity.

News

Could clinical trials be a safe healthcare space for the LGBTQ+ community?

June 30, 2025

By Stephanie Anderson, Chief of Staff Representation in clinical trials is crucial for equitable healthcare. Yet, the nature of clinical trial sites, which have historically been based in municipal centers … Read more

Dr. Rosenstock is the Lead Investigator for Lilly’s ACHIEVE-1 Trial for Oral GLP-1, Orforglipron, Results Published in NEJM

June 23, 2025

Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly’s Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight … Read more

Velocity Joins Advarra’s Council for Responsible Use of AI in Clinical Trials as Founding Member

June 18, 2025

We’re proud to share that Velocity Clinical Research has joined Advarra’s newly launched Council for Responsible Use of AI in Clinical Trials as a founding member—alongside fellow industry leaders from … Read more

BioSpace Article: U.S. Uncertainty Creates Clinical Trial Leadership Opportunity for Europe

June 17, 2025

The U.S. clinical research landscape faces uncertainty. NIH grant cancellations, FDA staffing cuts, and regulatory uncertainty are creating real challenges for the industry’s traditional leader. Europe has an opportunity if … Read more

Quality. Continuity. Velocity.